Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 42 clinical trials
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

a catheter: A plastic tube will be inserted into a vein in the neck or upper chest. They will get antibody therapy or chemotherapy. Recipients will get the transplant through their catheter

cancer
pulmonary function tests
bone marrow procedure
filgrastim
oxygen saturation
  • 3 views
  • 01 Apr, 2021
  • 2 locations
Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

> Recipients will have: More bone marrow and a small fragment of bone removed Dental, diet, and social worker consultations Scans Chemotherapy and antibody therapy

bone marrow transplant
bone marrow procedure
tacrolimus
thrombocytopenia
neutropenia
  • 138 views
  • 03 Apr, 2021
  • 2 locations
HPV-16/18 E6/E7-Specific T Lymphocytes Relapsed HPV-Associated Cancers HESTIA

lymphodepleted environment. Nivolumab is an antibody therapy that helps T cells control the tumor and it is FDA approved for the treatment of certain types of cancers, including Hodgkin's lymphoma

  • 10 views
  • 27 Jan, 2021
  • 1 location
Regorafenib With Cetuximab or Panitumumab for the Treatment of Unresectable Locally Advanced or Metastatic Colorectal Cancer

This phase II trial how well regorafenib and anti-EGFR therapy (cetuximab or panitumumab) works for the treatment of patients with colorectal cancer that cannot be removed by surgery (unresectable), has spread to nearby tissue or lymph nodes (locally advanced), or has spread to other places in the body (metastatic). Regorafenib …

  • 0 views
  • 15 Feb, 2021
  • 15 locations
De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma

The purpose of this study is to find out whether radiotherapy to some of the lymph node areas can be safely omitted to decrease side effects without increasing the risk of the tumour coming back.

ct scan
carcinoma
cancer
squamous cell carcinoma
oropharyngeal squamous cell carcinoma
  • 48 views
  • 14 Apr, 2021
  • 12 locations
Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)

The purpose of this study is to evaluate the safety of administration of plasma containing antibodies to the SARS-CoV-2 virus (i.e., convalescent plasma) and if it is able to prevent disease or lessen the severity of disease in individuals who are at high risk of developing COVID-19 due to a …

respiratory failure
nasopharyngeal swab
covid-19
SARS
  • 0 views
  • 25 Jan, 2021
  • 1 location
Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children

This is a multicentered, open-label, randomized controlled Phase 2 trial to evaluate the safety and efficacy of providing human coronavirus-immune convalescent plasma as treatment for COVID-19 disease in hospitalized children in the context of the COVID-19 pandemic.

covid-19
SARS
coronavirus infection
  • 45 views
  • 26 Jan, 2021
  • 14 locations
A Study of IMU-201 (PD1-Vaxx) a B-Cell Immunotherapy in Adults With Non-Small Cell Lung Cancer

The phase 1 study is an open label, multi-center, non-randomized, dose escalation and expansion study designed to assess the safety, tolerability, and immunogenicity of IMU-201(PD1-Vaxx) as monotherapy in patients with PD-L1 expressing non-small cell lung cancer (NSCLC).

carcinoma
cancer
measurable disease
pd-l1
kidney function test
  • 0 views
  • 29 Jan, 2021
  • 7 locations
A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer

In this phase II study, study subjects will receive the VRP-HER2 immunizations plus pembrolizumab. There will be an initial Safety Arm during which subjects will receive the VRP-HER2 immunizations plus pembrolizumab. If there is no dose limiting toxicity in the Safety Arm, then subjects will be randomized into 3 arms. …

HER2
erbb2
trastuzumab
measurable disease
metastasis
  • 5 views
  • 26 Jan, 2021
  • 1 location
JSP191 Antibody Targeting Conditioning in MDS/AML Patients Undergoing Hematopoietic Cell Transplantation

This is a Phase 1 study to evaluate the safety and tolerability of an antibody conditioning regimen known as JSP191, in combination with low dose radiation and fludarabine, in patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia undergoing blood stem cell transplantation

  • 0 views
  • 27 Jan, 2021
  • 6 locations